Replies to post #384500 on Elite Pharmaceuticals Inc (ELTP)

[mrwrn2010]

I asked specifically about market sizes / IMS numbers on the “needle mover” products and in which category they expect the biggest opportunity from (opioid, stimulant, etc.)

Also specifically asked if they have had further conversations with FDA/DEA and if so, do they anticipate us getting additional quota late this year or next.

Sent to Dianne already, prior to whatever the cutoff was. We’ll see!

[The ELTP King]

LMAO!

Revenue: +16.9%
Operating Profit: +60%
Net Income: +267%

The quarter ending 6/30/23 should show flat to small decline of revenue compared to 2022 results of 7.7 M total.

[The ELTP King]

LMAO!

Cash on hand:
March 31: $7,832,247
June 30: $9,076,659

the cash on hand which will show a significant decline as the company paid off the $11M loan.